Skip to content
ModernDoc
Get the app
Condition research / Explore another topicSaved preview · Not clinically reviewed
Myeloma.

The long view. The new questions.
A clearer understanding.

Study reading

Continuing zoledronic acid reduced bone disease progression

In a follow-up subgroup of the Magnolia trial, patients whose myeloma had reached a very good partial response or better after 2 years of zoledronic acid were assigned to continued monthly treatment or observation. Continued treatment reduced progressive bone disease. The result concerns this responding subgroup and does not establish the same benefit for patients with weaker responses. This was a follow-up subgroup analysis limited to patients with very good partial response or better after 2 years, so it does not establish the same effect for patients with lesser responses. The hazard ratio's 95% confidence interval was 0.16-0.92, leaving uncertainty about the size of the effect.

Evidence period: 2026 Sep2 min readAI-written · Not clinically reviewed

Saved revision 1 · · Revision history

In a follow-up subgroup of the Magnolia trial, patients whose myeloma had reached a very good partial response or better after 2 years of zoledronic acid were assigned to continued monthly treatment or observation. Continued treatment reduced progressive bone disease. The result concerns this responding subgroup and does not establish the same benefit for patients with weaker responses.

What the study found

In a follow-up subgroup of the Magnolia trial, patients whose myeloma had reached a very good partial response or better after 2 years of zoledronic acid were assigned to continued monthly treatment or observation. Continued treatment reduced progressive bone disease. The result concerns this responding subgroup and does not establish the same benefit for patients with weaker responses. Source ↗

Continued zoledronic acid reduced the risk of progressive bone disease, with a hazard ratio of 0.40 and a 95% confidence interval of 0.16-0.92. Source ↗

Who and what was studied

Patients who achieved a very good partial response or better after 2 years of zoledronic acid. Source ↗

Continued monthly zoledronic acid beyond 2 years was compared with observation. Source ↗

What remains uncertain

This was a follow-up subgroup analysis limited to patients with very good partial response or better after 2 years, so it does not establish the same effect for patients with lesser responses. The hazard ratio's 95% confidence interval was 0.16-0.92, leaving uncertainty about the size of the effect. Source ↗

Follow the evidence.

Source links and automated passage checks do not establish clinical review.

Supporting passages: Continuing zoledronic acid reduced bone disease progression

Continued monthly ZOL beyond 2 years significantly reduced the risk of PBD (hazard ratio 0.40; 95% confidence interval [CI] 0.16-0.92) in patients with VGPR or better (subgroup 1).

PMID 42581608 · abstract-1
Supporting passages: In a follow-up subgroup of the Magnolia trial, patients whose myeloma had reached a very good partial response or better after 2 years of zoledronic acid were assigned to continued monthly treatment or observation. Continued treatment reduced progressive bone disease. The result concerns this responding subgroup and does not establish the same benefit for patients with weaker responses. This was a follow-up subgroup analysis limited to patients with very good partial response or better after 2 years, so it does not establish the same effect for patients with lesser responses. The hazard ratio's 95% confidence interval was 0.16-0.92, leaving uncertainty about the size of the effect.

Two Magnolia trial subgroups were analysed: patients with VGPR or better after 2 years of ZOL, randomized to either continued treatment or observation, and patients randomized to observation in whom serial bone markers (C-terminal cross-linked telopeptide of type I collagen [CTX], procollagen type I N-terminal propeptide [P1NP], bone-specific alkaline phosphatase [BAP], tartrate-resistant acid phosphatase isoform 5b [TRAcP]) were measured for up to 4 years.

PMID 42581608 · abstract-1

Continued monthly ZOL beyond 2 years significantly reduced the risk of PBD (hazard ratio 0.40; 95% confidence interval [CI] 0.16-0.92) in patients with VGPR or better (subgroup 1).

PMID 42581608 · abstract-1
Supporting passages: In a follow-up subgroup of the Magnolia trial, patients whose myeloma had reached a very good partial response or better after 2 years of zoledronic acid were assigned to continued monthly treatment or observation. Continued treatment reduced progressive bone disease. The result concerns this responding subgroup and does not establish the same benefit for patients with weaker responses.

Two Magnolia trial subgroups were analysed: patients with VGPR or better after 2 years of ZOL, randomized to either continued treatment or observation, and patients randomized to observation in whom serial bone markers (C-terminal cross-linked telopeptide of type I collagen [CTX], procollagen type I N-terminal propeptide [P1NP], bone-specific alkaline phosphatase [BAP], tartrate-resistant acid phosphatase isoform 5b [TRAcP]) were measured for up to 4 years.

PMID 42581608 · abstract-1

Continued monthly ZOL beyond 2 years significantly reduced the risk of PBD (hazard ratio 0.40; 95% confidence interval [CI] 0.16-0.92) in patients with VGPR or better (subgroup 1).

PMID 42581608 · abstract-1
Supporting passages: In a follow-up subgroup of the Magnolia trial, patients whose myeloma had reached a very good partial response or better after 2 years of zoledronic acid were assigned to continued monthly treatment or observation. Continued treatment reduced progressive bone disease. The result concerns this responding subgroup and does not establish the same benefit for patients with weaker responses.

Two Magnolia trial subgroups were analysed: patients with VGPR or better after 2 years of ZOL, randomized to either continued treatment or observation, and patients randomized to observation in whom serial bone markers (C-terminal cross-linked telopeptide of type I collagen [CTX], procollagen type I N-terminal propeptide [P1NP], bone-specific alkaline phosphatase [BAP], tartrate-resistant acid phosphatase isoform 5b [TRAcP]) were measured for up to 4 years.

PMID 42581608 · abstract-1

Continued monthly ZOL beyond 2 years significantly reduced the risk of PBD (hazard ratio 0.40; 95% confidence interval [CI] 0.16-0.92) in patients with VGPR or better (subgroup 1).

PMID 42581608 · abstract-1
Supporting passages: Continued zoledronic acid reduced the risk of progressive bone disease, with a hazard ratio of 0.40 and a 95% confidence interval of 0.16-0.92.

Continued monthly ZOL beyond 2 years significantly reduced the risk of PBD (hazard ratio 0.40; 95% confidence interval [CI] 0.16-0.92) in patients with VGPR or better (subgroup 1).

PMID 42581608 · abstract-1
Supporting passages: Patients who achieved a very good partial response or better after 2 years of zoledronic acid.

Two Magnolia trial subgroups were analysed: patients with VGPR or better after 2 years of ZOL, randomized to either continued treatment or observation, and patients randomized to observation in whom serial bone markers (C-terminal cross-linked telopeptide of type I collagen [CTX], procollagen type I N-terminal propeptide [P1NP], bone-specific alkaline phosphatase [BAP], tartrate-resistant acid phosphatase isoform 5b [TRAcP]) were measured for up to 4 years.

PMID 42581608 · abstract-1
Supporting passages: Continued monthly zoledronic acid beyond 2 years was compared with observation.

Two Magnolia trial subgroups were analysed: patients with VGPR or better after 2 years of ZOL, randomized to either continued treatment or observation, and patients randomized to observation in whom serial bone markers (C-terminal cross-linked telopeptide of type I collagen [CTX], procollagen type I N-terminal propeptide [P1NP], bone-specific alkaline phosphatase [BAP], tartrate-resistant acid phosphatase isoform 5b [TRAcP]) were measured for up to 4 years.

PMID 42581608 · abstract-1

Continued monthly ZOL beyond 2 years significantly reduced the risk of PBD (hazard ratio 0.40; 95% confidence interval [CI] 0.16-0.92) in patients with VGPR or better (subgroup 1).

PMID 42581608 · abstract-1
Supporting passages: This was a follow-up subgroup analysis limited to patients with very good partial response or better after 2 years, so it does not establish the same effect for patients with lesser responses. The hazard ratio's 95% confidence interval was 0.16-0.92, leaving uncertainty about the size of the effect.

Two Magnolia trial subgroups were analysed: patients with VGPR or better after 2 years of ZOL, randomized to either continued treatment or observation, and patients randomized to observation in whom serial bone markers (C-terminal cross-linked telopeptide of type I collagen [CTX], procollagen type I N-terminal propeptide [P1NP], bone-specific alkaline phosphatase [BAP], tartrate-resistant acid phosphatase isoform 5b [TRAcP]) were measured for up to 4 years.

PMID 42581608 · abstract-1

Continued monthly ZOL beyond 2 years significantly reduced the risk of PBD (hazard ratio 0.40; 95% confidence interval [CI] 0.16-0.92) in patients with VGPR or better (subgroup 1).

PMID 42581608 · abstract-1
  1. Bone progression in multiple myeloma: Benefit of zoledronic acid for patients achieving at least Very Good Partial Response and prognostic value of bone turnover markers. ↗

    2026 Sep

    Source checked: 2026-09-15

There’s more to the story.

Study readings

Daratumumab combination produced more deep treatment responses

Patients with newly diagnosed multiple myeloma who were not having an initial transplant received a combination including daratumumab or the comparison combination without it. More patients receiving daratumumab reached complete response or better and tested negative for minimal residual disease. These responses were more often sustained, while progression-free survival among patients testing negative showed only a nonsignificant trend favoring daratumumab. The trial enrolled patients who were transplant-ineligible or deferred transplant as initial therapy, so it does not establish the same result for all newly diagnosed patients. Among patients who achieved minimal-residual-disease negativity, the progression-free-survival difference was not statistically significant, so an advantage in that subgroup remains uncertain. The median follow-up was 58.7 months, so outcomes beyond that period are not established.

2 min read · 2026 Aug 25

Study readings

Elotuzumab regimens showed mixed side-effect risks

A systematic review pooled randomized trials comparing elotuzumab-containing regimens with control therapies in multiple myeloma. The elotuzumab regimens had higher risks of pneumonia, diarrhea and infections, but lower neutropenia. Higher-grade lymphopenia, diarrhea, pneumonia, cataracts and infections were also more common; however, longer treatment and corticosteroid use may have influenced some differences. The analysis compared elotuzumab-containing regimens, not elotuzumab alone; longer treatment and corticosteroid use may have influenced differences, so effects cannot be assigned solely to elotuzumab. Higher risks included pneumonia, diarrhea and infections; grade 3-4 lymphopenia, diarrhea, pneumonia, cataracts and infections were also increased.

2 min read · 2026 Dec

A publication for curiosity.

AI-written. Not clinically reviewed. Selected sources, not a complete review. No personal treatment matching.

Article revisions preserve earlier writing. Article dates and source-check dates describe different events. Email updates and automatic research refresh are unavailable during this pilot.